Phase II Single-Arm Trial of Cladribine and Low-Dose Cytarabine Alternating with Decitabine as Frontline Therapy for Older Patients with Acute Myeloid Leukemia

BACKGROUND: Frontline therapy for older and/or unfit patients with acute myeloid leukemia (AML) remains unsatisfactory. We studied a new lower-intensity regimen of cladribine combined with low-dose cytarabine (LDAC) alternating with decitabine (DAC) aimed to improve outcomes in this population Based...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Lancet Haematol
Asıl Yazarlar: Kadia, Tapan M., Cortes, Jorge, Ravandi, Farhad, Jabbour, Elias, Konopleva, Marina, Benton, Christopher B., Burger, Jan, Borthakur, Gautam, DiNardo, Courtney D., Pemmaraju, Naveen, Daver, Naval, Ferrajoli, Alessandra, Wang, Xuemei, Patel, Keyur, Jorgensen, Jeffrey L., Wang, Sa, O’Brien, Susan, Pierce, Sherry, Tuttle, Carla, Estrov, Zeev, Verstovsek, Srdan, Garcia-Manero, Guillermo, Kantarjian, Hagop
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2018
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6775639/
https://ncbi.nlm.nih.gov/pubmed/30115541
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2352-3026(18)30132-7
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller